vs
ADMA BIOLOGICS, INC.（ADMA）与MARCUS CORP（MCS）财务数据对比。点击上方公司名可切换其他公司
MARCUS CORP的季度营收约是ADMA BIOLOGICS, INC.的1.4倍（$193.5M vs $139.2M），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 2.8%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $26.4M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 18.2%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
ADMA vs MCS — 直观对比
营收规模更大
MCS
是对方的1.4倍
$139.2M
营收增速更快
ADMA
高出15.6%
2.8%
自由现金流更多
ADMA
多$8.2M
$26.4M
两年增速更快
ADMA
近两年复合增速
18.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $193.5M |
| 净利润 | $49.4M | — |
| 毛利率 | 63.8% | — |
| 营业利润率 | 45.1% | 0.9% |
| 净利率 | 35.5% | — |
| 营收同比 | 18.4% | 2.8% |
| 净利润同比 | -55.9% | — |
| 每股收益（稀释后） | $0.20 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAMCS
| Q4 25 | $139.2M | $193.5M | ||
| Q3 25 | $134.2M | $210.2M | ||
| Q2 25 | $122.0M | $206.0M | ||
| Q1 25 | $114.8M | $148.8M | ||
| Q4 24 | $117.5M | $188.3M | ||
| Q3 24 | $119.8M | $232.7M | ||
| Q2 24 | $107.2M | $176.0M | ||
| Q1 24 | $81.9M | $138.5M |
净利润ADMAMCS
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $16.2M | ||
| Q2 25 | $34.2M | $7.3M | ||
| Q1 25 | $26.9M | $-16.8M | ||
| Q4 24 | $111.9M | $986.0K | ||
| Q3 24 | $35.9M | $23.3M | ||
| Q2 24 | $32.1M | $-20.2M | ||
| Q1 24 | $17.8M | $-11.9M |
毛利率ADMAMCS
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
营业利润率ADMAMCS
| Q4 25 | 45.1% | 0.9% | ||
| Q3 25 | 38.0% | 10.8% | ||
| Q2 25 | 35.1% | 6.3% | ||
| Q1 25 | 30.4% | -13.7% | ||
| Q4 24 | 32.6% | -1.2% | ||
| Q3 24 | 33.1% | 14.1% | ||
| Q2 24 | 36.6% | 1.3% | ||
| Q1 24 | 26.7% | -12.0% |
净利率ADMAMCS
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | 7.7% | ||
| Q2 25 | 28.1% | 3.6% | ||
| Q1 25 | 23.4% | -11.3% | ||
| Q4 24 | 95.2% | 0.5% | ||
| Q3 24 | 30.0% | 10.0% | ||
| Q2 24 | 29.9% | -11.5% | ||
| Q1 24 | 21.7% | -8.6% |
每股收益（稀释后）ADMAMCS
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.15 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.15 | — | ||
| Q2 24 | $0.13 | — | ||
| Q1 24 | $0.08 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $23.4M |
| 总债务越低越好 | $72.1M | $159.0M |
| 股东权益账面价值 | $477.3M | $457.4M |
| 总资产 | $624.2M | $1.0B |
| 负债/权益比越低杠杆越低 | 0.15× | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资ADMAMCS
| Q4 25 | $87.6M | $23.4M | ||
| Q3 25 | $61.4M | $7.4M | ||
| Q2 25 | $90.3M | $14.9M | ||
| Q1 25 | $71.6M | $11.9M | ||
| Q4 24 | $103.1M | $40.8M | ||
| Q3 24 | $86.7M | $28.4M | ||
| Q2 24 | $88.2M | $32.8M | ||
| Q1 24 | $45.3M | $17.3M |
总债务ADMAMCS
| Q4 25 | $72.1M | $159.0M | ||
| Q3 25 | $72.4M | $162.0M | ||
| Q2 25 | — | $179.9M | ||
| Q1 25 | — | $198.9M | ||
| Q4 24 | $72.3M | $159.1M | ||
| Q3 24 | — | $173.1M | ||
| Q2 24 | — | $175.7M | ||
| Q1 24 | — | $169.8M |
股东权益ADMAMCS
| Q4 25 | $477.3M | $457.4M | ||
| Q3 25 | $431.2M | $454.3M | ||
| Q2 25 | $398.3M | $448.4M | ||
| Q1 25 | $373.4M | $441.8M | ||
| Q4 24 | $349.0M | $464.9M | ||
| Q3 24 | $231.9M | $462.3M | ||
| Q2 24 | $188.3M | $449.4M | ||
| Q1 24 | $153.7M | $459.3M |
总资产ADMAMCS
| Q4 25 | $624.2M | $1.0B | ||
| Q3 25 | $568.7M | $1.0B | ||
| Q2 25 | $558.4M | $1.0B | ||
| Q1 25 | $510.6M | $1.0B | ||
| Q4 24 | $488.7M | $1.0B | ||
| Q3 24 | $390.6M | $1.0B | ||
| Q2 24 | $376.4M | $1.1B | ||
| Q1 24 | $350.9M | $1.0B |
负债/权益比ADMAMCS
| Q4 25 | 0.15× | 0.35× | ||
| Q3 25 | 0.17× | 0.36× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | 0.21× | 0.34× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.39× | ||
| Q1 24 | — | 0.37× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $48.8M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $26.4M |
| 自由现金流率自由现金流/营收 | 24.8% | 13.6% |
| 资本支出强度资本支出/营收 | 0.8% | 11.6% |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | $989.0K |
8季度趋势，按日历期对齐
经营现金流ADMAMCS
| Q4 25 | $35.6M | $48.8M | ||
| Q3 25 | $13.3M | $39.1M | ||
| Q2 25 | $21.1M | $31.6M | ||
| Q1 25 | $-19.7M | $-35.3M | ||
| Q4 24 | $50.2M | $52.6M | ||
| Q3 24 | $25.0M | $30.5M | ||
| Q2 24 | $45.6M | $36.0M | ||
| Q1 24 | $-2.2M | $-15.1M |
自由现金流ADMAMCS
| Q4 25 | $34.6M | $26.4M | ||
| Q3 25 | $-1.1M | $18.2M | ||
| Q2 25 | $18.7M | $14.7M | ||
| Q1 25 | $-24.4M | $-58.3M | ||
| Q4 24 | $47.5M | $27.1M | ||
| Q3 24 | $24.0M | $12.0M | ||
| Q2 24 | $43.6M | $16.1M | ||
| Q1 24 | $-4.6M | $-30.5M |
自由现金流率ADMAMCS
| Q4 25 | 24.8% | 13.6% | ||
| Q3 25 | -0.8% | 8.7% | ||
| Q2 25 | 15.3% | 7.1% | ||
| Q1 25 | -21.2% | -39.2% | ||
| Q4 24 | 40.4% | 14.4% | ||
| Q3 24 | 20.0% | 5.2% | ||
| Q2 24 | 40.7% | 9.2% | ||
| Q1 24 | -5.6% | -22.0% |
资本支出强度ADMAMCS
| Q4 25 | 0.8% | 11.6% | ||
| Q3 25 | 10.7% | 9.9% | ||
| Q2 25 | 2.0% | 8.2% | ||
| Q1 25 | 4.1% | 15.5% | ||
| Q4 24 | 2.3% | 13.5% | ||
| Q3 24 | 0.9% | 7.9% | ||
| Q2 24 | 1.9% | 11.3% | ||
| Q1 24 | 2.9% | 11.1% |
现金转化率ADMAMCS
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 2.41× | ||
| Q2 25 | 0.62× | 4.32× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | 53.31× | ||
| Q3 24 | 0.70× | 1.31× | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
